Charged Alpha Stock Encyclopedia

Elevance Health (ELV) Q3 2026 — Saved October 21, 12:32:21 CDT intraday quote: $440.71, up 0.12% versus the $440.18 prior close; session incomplete.
Elevance raised adjusted EPS guidance to at least $29, but its 2027 growth claim starts from a $26.75 recurring baseline. We separate nonoperating benefits, medical economics, working-capital timing and cash available to owners.
THE CALL: HOLD (3/5, MEDIUM) — Analyst central fair value ~$420 vs ~$440.71 October 21, 12:32:21 CDT intraday.
KEY METRICS:
- Operating revenue $50.440B, up 0.7%
- Adjusted EPS $6.99 includes $1.85 nonoperating benefit
- $29 headline floor versus $26.75 recurring baseline
- Benefit ratio 90.6%, 70bp better; adjusted operating gain down 0.5%
- YTD OCF $7.512B; working-capital swing $5.537B
- HOLD, 3/5 conviction; central $420; High uncertainty
What to watch: Reassess on the comparable 2027 outlook, recurring cash and parent distributions.
Full research packet: https://chargedalpha.com/research/elv-q3-2026
Also on YouTube: @ChargedAlpha
DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

NextEra Energy (NEE) Q3 2026 — The valuation uses the $78.86 October 20 regular close before the release; the unfinished October 21 session is excluded.
NextEra Energy grew adjusted EPS 9.7%, while hedge gains made reported growth look much larger. The investment question is how attractive operating growth is financed and what it earns for each share.
THE CALL: HOLD (3/5, MODERATE) — base-case value ~$80 vs ~$78.86 Oct 20 pre-release close.
KEY METRICS:
- Adjusted EPS $1.24 versus $1.13, up 9.7%
- GAAP EPS $2.28 includes substantial hedge gains
- 9M operating cash flow $12.322B; broad deployment $27.554B
- September 30 net debt $108.353B, computed
- Renewables/storage backlog 36.7GW; new origination 3.7GW
- Dominion closing expected second half 2027, subject to remaining approvals
What to watch: Review at or below $64 with project economics and financing intact, or after stronger operating and funding evidence supports a higher value.
Full research packet: https://chargedalpha.com/research/nee-q3-2026
Also on YouTube: @ChargedAlpha
DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Abbott Laboratories (ABT) Q3 2026 — Saved October21 09:58:28CDT intraday quote$98.135, down4.21% versus prior close; not a completed-session return.
Abbott reported14.5% sales growth and9.2% adjusted EPS growth, while GAAP earnings fell. We separate acquisition effects, specified charges and financing before valuing shareholder cash.
THE CALL: HOLD (3/5, MEDIUM) — Analyst central fair value ~$90 vs ~$98.135 October21 09:58:28CDT intraday quote.
KEY METRICS:
- Sales$13.013B +14.5%; comparable growth7.0%
- Adjusted EPS$1.42 +9.2%; GAAP EPS$0.53
- Pretax specifieds$1.689B include$841M amortization
- Latest net debt$27.005B datedJune30
- Nutrition separation targets end2027; terms matter
- HOLD3/5; $90 central; High uncertainty
What to watch: Reassess on verified cash conversion, debt reduction and executable Nutrition separation terms.
Full research packet: https://chargedalpha.com/research/abt-q3-2026
Also on YouTube: @ChargedAlpha
DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Netflix, Inc. (NFLX) Q3 2026 — Saved October 20 regular close $68.69, down 1.66% before released results. This is not an earnings-reaction return; later bid/ask is indicative only.
Netflix grew operating profit strongly, but expense timing, last year’s Brazil charge and a merger termination receipt complicate the comparison. We test recurring cash against the price.
THE CALL: SELL (3/5, MEDIUM) — Analyst central fair value ~$55 vs ~$68.69 October20 regular close before released results.
KEY METRICS:
- Revenue $12.87B, up 11.8%; operating profit $4.46B
- Prior Brazil charge $619M; current margin aided by expense timing
- Advertising outlook $2.7B versus roughly $3.0B
- Annual FCF guide $12B includes $2.8B termination receipt
- Central value $55 versus dated pre-release close $68.69
- SELL; conviction 3/5; High uncertainty
What to watch: Reassess on verified advertising execution, recurring cash and disciplined content investment.
Full research packet: https://chargedalpha.com/research/nflx-q3-2026
Also on YouTube: @ChargedAlpha
DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Stride, Inc. (LRN) Q1 FY2027 — Saved October 20 regular close $78.95, down 2.5% before reported results. This is not a post-earnings return; exact release minute is unconfirmed.
Stride reported higher GAAP EPS while enrollment and adjusted earnings declined. We trace the compensation credit, share counts, seasonal cash and convertible obligations.
THE CALL: HOLD (3/5, MEDIUM) — Analyst central fair value ~$80 vs ~$78.95 October 20 regular close before the reported results.
KEY METRICS:
- Revenue $639.4M, up 3.0%; school enrollment 241.4K, down 2.5%
- GAAP EPS $1.45 versus adjusted EPS $1.37; distinct denominators
- GAAP operating profit up 22.2%; adjusted operating profit down 3.1%
- Quarter operating cash −$124.8M; cash plus current securities $789.2M
- Central fair value $80 versus dated pre-release close $78.95
- HOLD; conviction 3/5; High uncertainty
What to watch: Reassess on durable adjusted-profit improvement, seasonal cash recovery and disciplined settlement.
Full research packet: https://chargedalpha.com/research/lrn-q1-fy2027
Also on YouTube: @ChargedAlpha
DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Space Exploration Technologies Corp. (SPCX) Q3 2026 — The $147.79 completed-close reference predates the release; no executed post-release reaction is asserted.
SpaceX turned profitable, but adjusted EBITDA exceeded operating income by $6.018 billion. We unpack depreciation, acquisition equity awards and cash conversion, then value both economic share classes.
THE CALL: SELL (3/5, MODERATE) — base-case value ~$85.00 vs ~$147.79 today.
KEY METRICS:
- Revenue $14.575B, +161.4% YoY
- GAAP operating income $2.791B; adjusted EBITDA $8.809B
- Quarter simple FCF −$9.962B, computed OCF less PP&E
- September economic shares: 13.579B, Class A plus B
- Analyst base $85; weighted scenarios $97.50; Very High uncertainty
What to watch: Reassess if Connectivity margin stays at least 42%, SI operating margin reaches 8%, and quarter simple FCF improves beyond negative $8B; recompute value with updated economic shares.
Full research packet: https://chargedalpha.com/research/spcx-q3-2026
Also on YouTube: @ChargedAlpha
DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Annaly Capital Management, Inc. (NLY) Q3 2026 — The saved October 20 regular-session close was $18.29, up 3.2% before the after-close release. This is not an earnings-response return. The exact release minute is unconfirmed.
Annaly earned more than its dividend on its non-GAAP EAD measure, but common book value fell 11.4%. We separate recurring carry from mortgage marks, funding exposure and value per share.
THE CALL: HOLD (2/5, LOW) — Analyst central fair value ~$17 vs ~$18.29 Oct 20, 2026 regular-session close; before after-close release.
KEY METRICS:
- Non-GAAP EAD $0.80 vs dividend $0.75
- GAAP EPS negative $1.36
- Book $17.86, down 11.4%; economic return negative 7.6%
- Economic leverage 5.9×; economic spread 1.42%
- Central value $17 vs dated pre-release close $18.29
- HOLD 2/5; High uncertainty
What to watch: Reassess on stable book, stronger underlying spread and sustained per-share dividend coverage. A lower price alone is insufficient.
Full research packet: https://chargedalpha.com/research/nly-q3-2026
Also on YouTube: @ChargedAlpha
DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Pegasystems Inc. (PEGA) Q3 2026 — At October 20, 2026, 16:00:19 CDT, the saved after-hours bid was $34.77 and ask $34.88. Their rounded midpoint was $34.83, 3.9% below the $36.23 regular close. This is an indicative quote, not a trade or completed post-release session return.
Pega Cloud ACV grew 20%, but total contract growth and cash tell a more cautious story. We value cash after an explicit compensation charge and explain the unresolved Appian retrial.
THE CALL: SELL (3/5, MODERATE) — Analyst central fair value ~$28 vs ~$34.83 Oct 20, 2026 16:00:19 CDT indicative bid/ask midpoint; not a trade.
KEY METRICS:
- Total ACV $1.653B,+6% reported;+7% constant currency
- Cloud ACV+20%; 59% of total
- Quarter GAAP EPS $0.08; adjusted $0.35
- Nine-month FCF $289.8M, down 14.3%
- TTM FCF less SBC proxy $297.5M
- Central value $28; Very High uncertainty; SELL3/5
What to watch: Reassess on faster total ACV, stronger cash after compensation and documented legal developments. A 30% margin of safety to the $28 base implies $19.60 only while the operating and legal thesis remains intact.
Full research packet: https://chargedalpha.com/research/pega-q3-2026
Also on YouTube: @ChargedAlpha
DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Intuitive Surgical, Inc. (ISRG) Q3 2026 — The October 20, 2026, 20:51:22 UTC after-hours trade was $407.90, down 6.87% from the $438 regular-session close.
Intuitive Surgical grew procedures and raised its margin outlook, yet the quarter carries a $450 million settlement charge. The settlement still needs court approval, and tariff refunds also lift adjusted earnings. What growth does the stock price already require?
THE CALL: HOLD (3/5, MODERATE) — base-case value ~$390.00 vs ~$407.90 today.
KEY METRICS:
- Revenue $3,048.7M, +21.70% YoY
- Worldwide da Vinci procedure growth approximately 14%
- GAAP EPS $1.49; adjusted EPS $3.00 includes $0.06 tariff-refund benefit
- Specific settlement charge $450M pre-tax; court approval pending
- Cash and investments $6,800.4M
What to watch: Review an upgrade near $312 with the thesis intact, or on verified forward owner cash generation above the $3.5B base assumption.
Full research packet: https://chargedalpha.com/research/isrg-q3-2026
Also on YouTube: @ChargedAlpha
DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

3M Company (MMM) Q3 2026 — At 11:51:37 CDT on October 20, MMM traded at $172.72, 6.61% above the $162.01 October 19 close. This is an intraday observation, not a closing return.
3M’s operating improvement is real, but reported and adjusted cash tell different stories. We test how much reaches common shareholders after legacy obligations, investment and minority claims.
THE CALL: HOLD (3/5, MODERATE) — Analyst central fair value ~$150 vs ~$172.72 Oct 20, 2026 11:51:37 CDT intraday.
KEY METRICS:
- GAAP revenue $6.584B; adjusted organic growth 3.3%
- Adjusted EPS $2.50 versus recast $2.23; GAAP EPS $2.63
- Quarter reported FCF $230M versus adjusted FCF $1.197B
- Recorded PFAS and earplug liabilities $8.6B; not maximum loss
- Net borrowing debt $9.852B; separate venture minority claims
- Price $172.72 at Oct 20, 2026 11:51:37 CDT; intraday
What to watch: Reassess on stronger reported cash after investment and obligations, sustained margins and lower net borrowing debt. $112.50 provides a 25% margin of safety to the $150 base only while the thesis remains intact.
Full research packet: https://chargedalpha.com/research/mmm-q3-2026
Also on YouTube: @ChargedAlpha
DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.